Current tools for monitoring response to tuberculosis treatments have several limitations. Noninvasive biomarkers could accelerate tuberculosis drug development and clinical studies, but to date little progress has been made in developing new imaging technologies for this application. In this study, we developed pulmonary single-photon emission computed tomography (SPECT) using radioiodinated DPA-713 to serially monitor the activity of tuberculosis treatments in live mice, which develop necrotic granulomas and cavitary lesions. C3HeB/FeJ mice were aerosol infected with Mycobacterium tuberculosis and administered either a standard or a highly active bedaquiline-containing drug regimen. 
R
ecognizing that tuberculosis (TB) is still a leading cause of human death from a curable disease, the international health community has set an ambitious target to eliminate TB by 2050. However, using mathematical modeling, Dye and Williams at the World Health Organization have shown that while most TB patients can be cured with current drug treatments, the 2050 target cannot be achieved with current tools and requires a combination of new diagnostics, shorter TB drug treatments, and new vaccines (1) . However, current tools for evaluating TB therapeutics have several limitations. Conventional preclinical studies are limited to analysis of serial postmortem samples using microbiologic methods that take 3 to 4 weeks for results. Moreover, different groups of animals are sacrificed over several time points during the study, and therefore, assessments of disease in the same animal can never be made. Similar limitations exist for monitoring TB treatments in humans. The standard 8-week sputum culture conversion is not available in real time, taking several weeks for results. Even though nucleic acid amplification tests such as GeneXpert provide results rapidly (2) , both sputum culture and GeneXpert are subject to sampling bias and provide information only about the lesions communicating with the airways. Noncommunicating pulmonary or extrapulmonary lesions are often never assessed. Similarly, assessment for relapse can require monitoring hundreds of patients for up to 2 years after treatment completion. With increasing rates of multidrug-resistant, extensively drug-resistant, and totally drug-resistant TB (3, 4) , it is imperative to develop even better tools to monitor treatment responses and predict relapse.
Noninvasive imaging provides rapid, three-dimensional views of the whole body, as well as the ability to monitor disease in the same individual. Real-time, longitudinal assessments can also provide new insights into the pathophysiology of disease, which may be difficult to assess with current technologies. Computed tomography (CT) and 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) are being increasingly used to monitor TB (5) (6) (7) (8) , in both preclinical and clinical settings. However, both CT and 18 F-FDG PET lack specificity, and 18 F-FDG is taken up by all glycolytically active tissues (9) (10) (11) . Since activated macrophages are key components of TB-associated inflammation, macrophage-avid tracers could serve as more specific imaging agents.
The translocator protein (TSPO) is an 18-kDa trans-mitochondrial membrane channel utilized for transport of cholesterol and other endogenous ligands (12) . TSPO expression is high in several tissues and in activated immune cells such as microglia and macrophages (13) . We have previously demonstrated that radioiodinated DPA-713, a low-molecular-weight pyrazolopyrimidine ligand for TSPO, specifically accumulates in activated phagocytic cells in Mycobacterium tuberculosis-induced inflammatory lesions and is more specific than 18 F-FDG PET in mice (14) . In this study, we utilized serial 125 I-DPA-713 single-photon emission computed tomography (SPECT) to monitor the activity of a novel, bedaquilinecontaining TB drug regimen being developed against multidrug-resistant (MDR) TB (15) in live mice that develop necrotic and hypoxic TB lesions (16, 17) . Ex vivo studies were performed to characterize and correlate DPA-713 imaging with cellular and cytokine responses in different TB lesions, including cavities.
MATERIALS AND METHODS
All protocols were approved by the Johns Hopkins Biosafety, Radiation Safety, and Animal Care and Use Committees.
Animal infection and treatments. Four-to six-week-old female C3HeB/FeJ (Jackson Laboratory, Bar Harbor, ME) mice were aerosol infected with frozen stocks of M. tuberculosis H37Rv, using the Middlebrook inhalation exposure system (Glas-Col, Terre Haute, IN). Six weeks after infection, mice were randomly divided into treatment groups and orally administered (5 days per week) either the standard RHZ (rifampin, 10 mg/kg; isoniazid, 10 mg/kg; pyrazinamide, 150 mg/kg) or a highly active JZC (bedaquiline, 25 mg/kg; pyrazinamide, 150 mg/kg; clofazimine, 20 mg/kg) regimen for 12 and 8 weeks, respectively (Fig. 1 ). All TB drugs were obtained from Sigma (St. Louis, MO) except bedaquiline (Ͼ98% chemical purity), which was purchased from Adooq Bioscience LLC (Irvine, CA). Mice were sacrificed to determine the bacillary burden 1 day after infection and at each time point (14) . Both sides of the lungs were homogenized in 1 ml of phosphate-buffered saline, serially diluted, and plated onto Middlebrook 7H11 selective plates (Becton Dickinson, Franklin Lakes, NJ) to determine CFU per ml. Five mice were used for each group and at each time point, except at the 4-week time point for the untreated group, where only 4 mice were used. A separate group of identically infected mice were used for imaging studies. A cohort of mice (n ϭ 13) receiving the standard (RHZ) treatment were also followed for 16 weeks after cessation of treatment and sacrificed to determine the pulmonary bacterial burden (entire lungs) at the final time point.
Imaging. 125 I-DPA-713 was synthesized in-house as described previously with Ͼ99% radiochemical purity and specific activities ranging from 66,600 to 77,700 GBq/mmol (18) . Live M. tuberculosis-infected animals were imaged within a sealed biocontainment bed (Minerve, Esternay, France) modified in-house to comply with biosafety level 3 (BSL-3) containment (5, 19) . Filters (0.22 m; GE Whatman, Pittsburgh, PA) were used at both the inlet and the outlet to contain the bacteria within the device. Animals were anesthetized and sealed inside the biocontainment device in the BSL-3 facility. A standard small-animal anesthesia machine was used to deliver an isoflurane (Henry Schein, Melville, NY)-oxygen mixture during transport and imaging. Prior to imaging, mice were fasted for 8 h. Each animal was weighed, injected intravenously with 7.3 MBq of 18 F-FDG and 37 MBq of 125 I-DPA-713 simultaneously via tail vein, and imaged 45 min and 24 h after the intravenous injection, using a Mosaic HP PET (Philips, Bothell, WA) and NanoSPECT/CT (Bioscan, Washington, DC) small-animal imager, respectively (PET, SPECT, and CT imaging of each animal at each time point). The same group of mice was imaged over several time points (outlined in Fig. 1 ). To prevent "cross talk" between PET and SPECT, 18 F-FDG PET was performed 45 min after injection on the first day. Due to its short half-life (109 min), 18 F decays completely by 24 h, when the 125 I-DPA-713 SPECT was performed. Also, the primary energies of 125 I (maximum of 35 keV) are much lower than those of 18 F (all PET tracers emit at 511 keV, resulting from electron-positron annihilation); photons from 125 I are excluded from the PET scan. Five mice were imaged for each group and at each time point except at week 0, when four mice were imaged (untreated group). Images were reconstructed and coregistered with computed tomography (CT) images using AMIDE 1.0.4 (http://amide.sourceforge.net). Standardized uptake values (SUV) were computed as described previously (14) . Briefly, by using the coregistered CT images as a reference, spherical (9-mm 3 volume) regions of interest (ROIs) were drawn around three randomly selected pulmonary lesions, making sure not to overlap the surrounding PET-active bone marrow or heart, creating 15 ROIs per group for each time point. These ROIs were applied to the coregistered SPECT and PET images. Since each spherical ROI contains both full and partial voxels depending on the orientation, correction for partial volume effects was applied to all imaging data using AMIDE. This is considered standard for image analyses. The SUV data are presented as a percentage of the signal noted at the initial time point (start of treatment).
Histology and immunofluorescence. DPA-713-IRDye680LT was administered to M. tuberculosis-infected mice (8 weeks after infection; no TB treatment) intravenously 24 h prior to euthanasia, and lungs were processed as described previously (14) . Paraffin-embedded formalin-fixed tissue sections were probed using fluorescent antibodies (see Table S1 in the supplemental material). A Nikon 80i upright epifluorescence microscope (Nikon Instruments, Melville, NY) equipped with a Nikon DSQi1Mc dark-field charge-coupled device (CCD) camera and Nikon Intensilight C-HGFI lamp was used. All images were recorded and processed using Nikon Imaging software elements.
Flow cytometry. DPA-713-IRDye680LT and brefeldin A (Sigma) were administered to a separate group of M. tuberculosis-infected mice (8 weeks after infection; no TB treatment) intravenously 24 and 6 h prior to euthanasia, respectively, as described previously (14, 20) . Lungs were harvested and processed as described previously (21) . Briefly, cells (2 ϫ 10 6 cells/well) were incubated with cell phenotype-specific markers (see Table  S1 in the supplemental material) in the presence of anti-FcRII/III antibody (1.3 g/ml) at 4°C for 1 h. Thereafter, cells were washed, fixed, and permeabilized for intracellular cytokine staining. Samples were analyzed on a LSR-II instrument (BD, San Jose, CA), and data were analyzed using FACSDiva v5.0.1 software (BD). The gating strategy for these analyses is shown in Fig. S1 in the supplemental material. A minimum of 10,000 events were acquired within each cell-specific gate. Samples from five different mice were utilized for these assays.
Cytokine estimation. Whole-lung homogenates from mice receiving TB treatments were frozen at Ϫ80°C. Samples were thawed and filter sterilized to remove tissue and bacterial debris. Tumor necrosis factor alpha (TNF-␣) and interferon gamma (IFN-␥) were assayed by using an enzyme-linked immunosorbent assay (ELISA) kit (R & D Systems, Minneapolis, MN). Protein content was estimated by using the Bradford assay. The cytokine concentrations are expressed as pg per mg of total protein. Samples from four different mice were utilized for each group and at each time point.
124 I-DPA-713 PET imaging. Clinical-grade 124 I-DPA-713 was synthesized using current good manufacturing practices (cGMP) under a research contract (3D Imaging, Maumelle, AR). Each mouse was weighed, injected intravenously with 13.5 MBq of 124 I-DPA-713 (Ͼ95% radiochemical purity; specific activity, 96,089 GBq/mmol), and imaged 24 h later using the Mosaic HP PET. Five mice were imaged for each group. Image analyses were performed as described above.
FIG 1 Timeline and experimental scheme. Six weeks after aerosol infection
with Mycobacterium tuberculosis, mice were randomly divided into treatment groups. Different animal cohorts received either the standard (RHZ) or a highly active bedaquiline-containing regimen (JZC). Animals receiving standard treatment were also followed for 16 weeks after the completion of treatment to monitor for relapse. Mice were serially imaged at weeks 0, 4, 8, and 12 to assess the bactericidal activity. A separate cohort of 13 animals which received 12 weeks of standard (RHZ) treatment were followed for the development of relapse and imaged at weeks 18 and 28 (6 and 16 weeks after cessation of TB treatment). The pulmonary bacterial burdens from a separate cohort of similarly infected and treated mice were determined using standard microbiology at each time point.
Statistical analysis. Statistical comparisons were performed using a two-tailed Mann-Whitney U or Kruskal-Wallis (for multiple comparisons) test and Spearman's rank correlation (GraphPad Software Inc., La Jolla, CA). P values of Ͻ0.05 were considered statistically significant.
RESULTS
Pulmonary M. tuberculosis bacillary burdens 1 day and 6 weeks (time of initiation of TB treatments) after infection were 2.00 Ϯ 0.13 and 8.05 Ϯ 0.02 log 10 CFU/ml, respectively.
125 I-DPA-713 SPECT imaging correlates with bactericidal activity of TB treatments. We evaluated serial 125 I-DPA-713 SPECT imaging to measure the response to a novel, bedaquilinecontaining TB drug regimen (JZC).
125 I-DPA-713 SPECT was compared with 18 F-FDG PET imaging and standard microbiology. M. tuberculosis-infected mice were serially imaged, generating 102 image sets (SPECT, PET, and CT). In agreement with the previously reported higher bactericidal activity of bedaquilinecontaining regimens (22) , 8 weeks of treatment with JZC cleared the infection in the majority of mice, versus 12 weeks required to achieve the same bacterial killing with the standard (RHZ) treatment ( Fig. 2A) . Pulmonary 125 I-DPA-713 SPECT activity correlated well with the decrease in the pulmonary bacterial burden (Spearman's ϭ 0.92; P Ͻ 0.01). Although 18 F-FDG PET could rapidly distinguish treated versus untreated animals (P Ͻ 0.01), it was unable to correctly identify the bactericidal activities of the two TB treatments (P Ͼ 0.49) (Fig. 2B) . In contrast, pulmonary 125 I-DPA-713 SPECT activity not only was able to rapidly distinguish the treated versus untreated groups (P Ͻ 0.01) but also correctly identified the bactericidal activities of the two TB regimens as early as 4 weeks after the start of treatment (P Ͻ 0.03) (Fig. 2C) .
A cohort of 13 M. tuberculosis-infected mice were imaged 6 and 16 weeks after completion of standard (RHZ) TB treatment to assess relapse. We hypothesized that for an ideal imaging biomarker, an increase in the mean pulmonary activity during relapse would correlate with the pulmonary bacterial burden. A total of 78 image sets (SPECT, PET, and CT) were analyzed to measure the change in the SUV between 6 and 16 weeks after cessation of TB treatment (SUVR 16week/6week ) and compared with postmortem pulmonary CFU at the final time point (Fig. 3) . A significant correlation was found between the interval increase in 125 I-DPA-713 SPECT activity for each animal with the pulmonary bacterial burden at relapse (Spearman's ϭ 0.79; P Ͻ 0.01). However, interval increase in 18 F-FDG PET activity did not correlate well with the pulmonary bacterial burden at relapse (Spearman's ϭ 0.34; P ϭ 0.26).
125 I-DPA-713 SPECT imaging of TB lesions. Since pulmonary TB is characterized by multiple different pathologies, we evaluated the ability of DPA-713 to detect and penetrate different TB lesions. Figure 4A to C show CT, 18 F-FDG PET/CT, and 125 I-DPA-713 SPECT/CT images from a mouse with pulmonary lesions 8 weeks after infection. Both (Fig. 4D) , with numerous intracellular and extracellular bacilli (Fig. 4E) and fibrosis around the rim (Fig. 4F) . Immunofluorescence analyses confirmed that intravenously injected DPA-713 penetrated into the cellular rim and colocalized with inflammatory cells (Fig. 4G to J) .
One month after the completion of RHZ treatment, pulmonary cavitary lesions were observed on CT imaging in 61% (11 of 18) of mice. As before, both 18 SPECT signals colocalized with the rim of the cavitary lesion ( Fig.  5A to C) . Postmortem histopathology demonstrated the cavity ( Fig. 5D and E), with numerous intracellular and extracellular bacilli ( Fig. 5F ) and prominent fibrosis around the rim ( Fig. 5G and H). Picrosirius red staining (23, 24) also suggested remodeling of the extracellular matrix (Fig. 5I) . Immunofluorescence analysis confirmed that intravenously injected DPA-713 penetrated into the cellular rim and colocalized with inflammatory cells (Fig. 5J to O) . Optical imaging in live animals followed by subsequent postmortem ex vivo whole-lung imaging also confirmed localization of DPA-713 with the TB lesions (see Fig. S2 in the supplemental material).
Correlation with cellular and cytokine responses. ϩ , and Gr-1 ϩ cells, respectively. Finally, we also determined cytokine levels in whole-lung homogenates from animals receiving TB treatments ( Fig. 6D and E) . There was a time-dependent decrease in both TNF-␣ and IFN-␥ levels during TB treatment.
125 I-DPA-713 SPECT imaging correlated best with tissue TNF-␣ levels (Spearman's ϭ 0.94; P Ͻ 0.01) (see Fig. S3A in the supplemental material) .
124 I-DPA-713 PET imaging. Although 125 I-DPA-713 SPECT imaging is excellent for preclinical assessments in mice, 125 I emits low-energy photons and lacks the tissue penetration needed for human imaging. However, iodo-DPA-713 can be labeled with positron-emitting ( 124 I) radioisotopes, ideal for PET imaging in humans. We therefore evaluated the uptake and distribution of 124 I-DPA-713 in mice (8 weeks after infection; no TB treatment). 124 I-DPA-713 PET demonstrated excellent localization of the radiotracer with TB lesions in M. tuberculosis-infected mice (Fig. 7) . 124 I-DPA-713 PET produced 4.0-fold-higher signal intensity in the infected TB lesions compared to healthy lungs (uninfected controls) (P ϭ 0.03). Three-dimensional coregistered 124 I-DPA-713 PET/CT movies demonstrated discrete areas of 124 I-DPA-713 PET signal in the infected lung tissues, with only minimal background signal in the uninfected animal (see Movies S1 and S2 in the supplemental material). 
DISCUSSION
Molecular imaging of TB pathology can provide valuable realtime information, which could allow early prediction of TB treatment responses and the development of relapse (25) . While current tomographic imaging techniques such as CT and 18 F-FDG PET can provide information on treatment responses by measuring the change in host immune responses that occur during treatment (5-8), they lack specificity, and 18 F-FDG is taken up by a wide range of inflammatory and noninflammatory cells. Since activated macrophages are key components of TB-associated inflammation, we hypothesized that real imaging with a macrophage-avid tracer such as radioiodo-DPA-713 would serve as a more specific biomarker technique to monitor the response to TB treatments. Pulmonary 125 I-DPA-713 SPECT demonstrated significant correlation with the bactericidal activities of TB treatments and was able to correctly identify the bactericidal activities (as early as 4 weeks) of the standard (RHZ) and a novel, highly active bedaquiline-containing TB regimen (JZC). We also found that an early increase in 125 I-DPA-713 SPECT activity, but not 18 F-FDG PET activity, correlated significantly with the bacterial burden at relapse. Collectively, these data suggest that iodo-DPA-713 imaging may be more specific for TB-associated inflammation than 18 F-FDG PET and could provide a better means of monitoring TB treatments.
After deposition of M. tuberculosis in the alveoli via an airborne route, initial events include bacterial phagocytosis by alveolar macrophages and other phagocytic cells, bacterial replication, development of delayed-type hypersensitivity, and the formation of the pulmonary granuloma (26) . With the emergence of delayedtype hypersensitivity (DTH), infected cells in the interior of the granuloma are killed, leading to the formation of the "classic" TB granuloma-an organized structure with central areas of caseous necrosis surrounded by dense infiltrates of neutrophils, activated macrophages, lymphocytes, and fibroblasts. Some lesions also expel their contents into airways to form cavitary lesions with high bacillary burdens (10 7 to 10 9 ), making the patient highly infectious (27) . Therefore, active pulmonary TB in humans is characterized by a complex spectrum of disease with multiple pathologies, including granulomas with caseous necrosis and cavitation (28, 29) . While standard mouse strains cannot recapitulate necrotic or cavitary pathologies, we and others have demonstrated that in addition to developing necrotic and hypoxic lesions, C3HeB/FeJ mice also develop cavitary TB (24, 30, 31) . Similar to human pathology, where granulomas are surrounded by a fibrotic capsule (32), extensive fibrosis was also noted around chronic TB granulomas and cavities in C3HeB/FeJ mice. Despite the fibrotic barrier, radiolabeled and fluorescent DPA-713 analogs readily penetrated the TB lesions, suggesting that radioiodinated DPA-713 could be used to detect and quantify TB-associated inflammatory responses in different TB lesions noninvasively.
Since DPA-713 accumulates specifically in activated inflammatory cells, we wanted to correlate the imaging findings with the inflammatory responses. We therefore characterized and correlated 125 I-DPA-713 SPECT with tissue cellular and cytokine responses in M. tuberculosis-infected lungs. As reported previously, the majority of DPA-713 ϩ cells were found to express CD68 (14 (14) . We also found that CD68 ϩ neutrophils comprised a significant proportion (17.7%) of the DPA-713 ϩ cells. Gottfried et al. and Amanzada et al. demonstrated that CD68 is not specific to macrophages and is a lysosomal protein enriched in activated macrophages, dendritic cell, granulocytes, and some fibroblasts (33, 34) . We also found that 18% of DPA-713 ϩ cells were CD11b ϩ Gr-1 ϩ inflammatory macrophages. Myeloid-derived suppressor cells (inflammatory macrophages) are characterized by the coexpression of CD11b and Gr-1, and a systemic expansion of these cells has been noted previously with TB (35) . Also, as expected, functionally active CD68 ϩ and DPA-713 ϩ cells had high levels of intracellular TNF-␣ and IFN-␥ expression, both of which are key cytokines in TB pathology (36) . Finally, we also determined cytokine levels from whole-lung homogenates of animals receiving TB treatments. A time-dependent decrease in both TNF-␣ and IFN-␥ levels was observed with TB treatments, and 125 I-DPA-713 SPECT imaging correlated best with TNF-␣ levels. It should be noted that while cytokines were determined from whole-lung homogenates, DPA-713 SPECT measured the activity in discrete lung lesions, which would presumably also be the predominant sites of cytokine production. Although 125 I-DPA-713 SPECT imaging is excellent for preclinical assessments in mice, 125 I emits low-energy photons and lacks the tissue penetration needed for human imaging. However, iodo-DPA-713 can be labeled with higher-energy direct ␥ ( 123 I) or positron-emitting ( 124 I) radioisotopes, ideal for SPECT or PET imaging in humans, respectively. We therefore utilized 124 I-DPA-713 manufactured under cGMP and demonstrated excellent PET signal-to-noise ratios for pulmonary TB lesions, suggesting that 124 I-DPA-713 PET is an excellent candidate imaging biomarker technique for TB-associated inflammation.
124 I-DPA-713 PET could be utilized for preclinical studies but also has the potential for translation to humans, especially in settings such as TB trials, where resources are not as limited but rapid, and accurate biomarkers for monitoring TB treatments and relapse are urgently required.
